1h Free Analyst Time
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin L plays a major role in antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation. Although commonly recognized as a lysosomal protease, cathepsin L is also secreted. The cathepsin L gene is activated by a variety of growth factors, tumor promoters, and second messengers. Cathepsin L promote tumor cell invasion and metastasis by catalyzing degradation of the interstitial matrix and basement membranes, thus allowing cancer cells to invade locally and metastasize to distant sites.Speak directly to the analyst to clarify any post sales queries you may have.
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 2 and 3 respectively. Report covers products from therapy areas Infectious Disease and Oncology which include indications Coronavirus Disease 2019 (COVID-19), Breast Cancer, Chagas Disease (American Trypanosomiasis), Ebolavirus Infections (Ebola Hemorrhagic Fever), Head And Neck Cancer Squamous Cell Carcinoma, Marburgvirus Infections (Marburg Hemorrhagic Fever), Metastatic Prostate Cancer, Middle East Respiratory Syndrome (MERS), Osteosarcoma, Paramyxoviridae Infections and Severe Acute Respiratory Syndrome (SARS).
The latest report Cathepsin L1 - Drugs In Development, 2022, outlays comprehensive information on the Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)
- The report reviews Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Overview
- Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Companies Involved in Therapeutics Development
- Landsteiner Genmed SL
- Oncotelic Therapeutics Inc
- Phelix Therapeutics LLC
- Selva Therapeutics Inc
- Sorrento Therapeutics Inc
- Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Drug Profiles
- Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Inhibitors of Cathepsin L - Drug Profile
- Product Description
- Mechanism Of Action
- KGP-207 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KGP-420 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KGP-94 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SLV-213 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- STI-1558 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Dormant Products
- Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Product Development Milestones
- Featured News & Press Releases
- Jul 19, 2022: Sorrento Therapeutics announces the FDA IND clearance of STI-1558, an oral M(pro) and Cathepsin L inhibitor to treat COVID-19
- Apr 20, 2022: Selva announces preclinical data confirming SLV213 potently inhibits infection by the SARS-CoV-2 omicron variant
- Jan 28, 2022: Sorrento announces its oral SARS-CoV-2 main protease (Mpro) inhibitor, STI-1558, strongly neutralizes omicron
- Jul 19, 2021: Selva to present preclinical data at ASV 2021 demonstrating prophylactic and therapeutic oral dosing of SLV213 for COVID-19 protected lungs from SARS-CoV-2-induced damage
- Jun 10, 2021: Selva’s Covid-19 drug shows activity against SARS-CoV-2 variants
- Feb 03, 2021: Selva Therapeutics reports positive data from Covid-19 treatment trial
- Nov 12, 2020: Selva Therapeutics announces first dosing in phase 1 clinical study of SLV213, a potential oral treatment for COVID-19
- Mar 31, 2017: Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017
- Apr 07, 2014: OXiGENE Announces Results of KGP94 Preclinical Studies at 2014 AACR Conference
- Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Landsteiner Genmed SL, 2022
- Pipeline by Oncotelic Therapeutics Inc, 2022
- Pipeline by Phelix Therapeutics LLC, 2022
- Pipeline by Selva Therapeutics Inc, 2022
- Pipeline by Sorrento Therapeutics Inc, 2022
- Dormant Products, 2022
- Dormant Products, 2022 (Contd..1)
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Landsteiner Genmed SL
- Oncotelic Therapeutics Inc
- Phelix Therapeutics LLC
- Selva Therapeutics Inc
- Sorrento Therapeutics Inc
